Loading...
XNASAEMD
Market cap8mUSD
Dec 27, Last price  
0.61USD
1D
3.06%
1Q
27.74%
Jan 2017
-99.04%
Name

Aethlon Medical Inc

Chart & Performance

D1W1MN
XNAS:AEMD chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
83.48%
Rev. gr., 5y
%
Revenues
0k
-100.00%
00000001,359,6211,230,0041,623,769762,417886,572392,073149,625229,625650,187659,104294,165574,2450
Net income
-12m
L+1.48%
-2,096,951-2,920,183-6,024,545-4,140,264-6,084,158-4,573,315-5,711,435-8,111,340-4,892,040-13,357,232-6,797,157-4,872,329-7,276,113-5,679,558-6,194,719-6,373,948-7,886,709-10,416,091-12,029,786-12,208,174
CFO
-10m
L-3.57%
-1,559,366-1,584,281-1,718,904-2,104,272-1,777,388-1,977,517-1,968,333-1,841,355-2,098,857-2,138,971-5,049,414-4,329,307-3,505,900-3,910,680-4,293,433-5,197,608-6,764,940-9,767,157-10,505,128-10,129,810
Earnings
Feb 12, 2025

Profile

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
URL
https://www.aethlonmedical.com/
IPO date
Mar 09, 1994
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
574
95.21%
294
-55.37%
Cost of revenue
10,117
15,483
13,210
Unusual Expense (Income)
NOPBT
(10,117)
(14,909)
(12,916)
NOPBT Margin
Operating Taxes
3
(5)
Tax Rate
NOPAT
(10,117)
(14,909)
(12,911)
Net income
(12,208)
1.48%
(12,030)
15.49%
(10,416)
32.07%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,322
8,927
17,368
BB yield
-31.33%
-1,136.42%
-806.12%
Debt
Debt current
291
269
127
Long-term debt
1,590
2,149
1,332
Deferred revenue
Other long-term liabilities
Net debt
(3,561)
(12,202)
(15,701)
Cash flow
Cash from operating activities
(10,130)
(10,505)
(9,767)
CAPEX
(251)
(943)
(349)
Cash from investing activities
(251)
(943)
(349)
Cash from financing activities
1,288
8,915
17,368
FCF
(9,719)
(16,067)
(13,848)
Balance
Cash
5,442
14,533
17,072
Long term investments
88
88
Excess cash
5,442
14,592
17,145
Stockholders' equity
(154,571)
(148,483)
(130,455)
Invested Capital
161,278
164,542
148,176
ROIC
ROCE
EV
Common stock shares outstanding
2,513
2,054
1,476
Price
1.68
339.22%
0.38
-73.80%
1.46
-28.08%
Market cap
4,221
437.38%
786
-63.54%
2,155
-12.22%
EV
660
(11,417)
(13,688)
EBITDA
(9,758)
(14,668)
(12,792)
EV/EBITDA
0.78
1.07
Interest
Interest/NOPBT